Literature DB >> 15839721

Safety and tolerability of oral erectile dysfunction treatments in the elderly.

Andrea Salonia1, Alberto Briganti, Piero Montorsi, Tommaso Maga, Federico Dehò, Giuseppe Zanni, Bruno Mazzoccoli, Nazareno Suardi, Patrizio Rigatti, Francesco Montorsi.   

Abstract

Erectile dysfunction (ED) is a common medical condition that affects the sexual life of millions of men worldwide. It is generally accepted that sexual function tends to decline with aging, which is often associated with a higher prevalence of sexual problems, including ED and loss of libido. As the mean age of men seeking medical help for sexual dysfunction continues to increase, it is important to assess the safety and tolerability of currently available medical treatments in elderly men, who often share other co-morbidities that should be carefully evaluated when any type of ED therapy is considered. With this aim in mind, a MEDLINE search was conducted from 1 January 1998 to 31 May 2004 to identify studies assessing the efficacy, safety and tolerability of treatments for ED in the elderly. Particular care was taken to assess the cardiovascular safety of oral drugs for ED in this subset of patients, who often have multiple cardiovascular risk factors which contribute to a complicated clinical scenario. The most important conclusion of the paper is that the high efficacy, reliability, safety and tolerability of oral ED treatments makes them appropriate first-line therapies for elderly patients with ED.

Entities:  

Mesh:

Year:  2005        PMID: 15839721     DOI: 10.2165/00002512-200522040-00005

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   4.271


  112 in total

1.  The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia.

Authors:  Julian P J Halcox; Khaled R A Nour; Gloria Zalos; Rita A Mincemoyer; Myron Waclawiw; Candido E Rivera; Georgia Willie; Samer Ellahham; Arshed A Quyyumi
Journal:  J Am Coll Cardiol       Date:  2002-10-02       Impact factor: 24.094

2.  Erectile and ejaculatory dysfunction in a community-based sample of men 50 to 78 years old: prevalence, concern, and relation to sexual activity.

Authors:  M H Blanker; J L Bosch; F P Groeneveld; A M Bohnen; A Prins; S Thomas; W C Hop
Journal:  Urology       Date:  2001-04       Impact factor: 2.649

3.  Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina.

Authors:  D J Webb; G J Muirhead; M Wulff; J A Sutton; R Levi; W W Dinsmore
Journal:  J Am Coll Cardiol       Date:  2000-07       Impact factor: 24.094

Review 4.  The mutually reinforcing triad of depressive symptoms, cardiovascular disease, and erectile dysfunction.

Authors:  I Goldstein
Journal:  Am J Cardiol       Date:  2000-07-20       Impact factor: 2.778

5.  A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction.

Authors:  Peter A Milligan; Scott F Marshall; Mats O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2002       Impact factor: 4.335

6.  The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.

Authors:  Gary J Muirhead; Keith Wilner; Wayne Colburn; Gertrude Haug-Pihale; Bernhard Rouviex
Journal:  Br J Clin Pharmacol       Date:  2002       Impact factor: 4.335

7.  The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil.

Authors:  I Saenz de Tejada; J Angulo; P Cuevas; A Fernández; I Moncada; A Allona; E Lledó; H G Körschen; U Niewöhner; H Haning; E Pages; E Bischoff
Journal:  Int J Impot Res       Date:  2001-10       Impact factor: 2.896

8.  Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.

Authors:  M Boolell; M J Allen; S A Ballard; S Gepi-Attee; G J Muirhead; A M Naylor; I H Osterloh; C Gingell
Journal:  Int J Impot Res       Date:  1996-06       Impact factor: 2.896

9.  Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction.

Authors:  S A Kaplan; R B Reis; I J Kohn; R Shabsigh; A E Te
Journal:  Urology       Date:  1998-11       Impact factor: 2.649

10.  Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses.

Authors:  Gerald B Brock; Chris G McMahon; K K Chen; Timothy Costigan; Wei Shen; Vish Watkins; Greg Anglin; Steve Whitaker
Journal:  J Urol       Date:  2002-10       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.